masoprocol has been researched along with Precancerous Conditions in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (66.67) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ashfaq, R; Bernstein, HS; Brock, M; Deasel, M; Dhara, S; Forastiere, A; Hansel, DE; Harmon, J; Huang, RC; Maitra, A; Montgomery, E; Shimada, Y; Washington, MK | 1 |
Denda, A; Endoh, T; Horiguchi, K; Kobayashi, E; Konishi, Y; Nakae, D; Noguchi, O; Ogasawara, H; Sugimura, M; Tamura, K; Tang, Q; Tsujiuchi, T | 1 |
Barnaby, JW; Cockerell, CJ; Styles, AR | 1 |
1 review(s) available for masoprocol and Precancerous Conditions
Article | Year |
---|---|
Actinic keratoses. Differential diagnosis and treatment.
Topics: Aging; Chemexfoliation; Combined Modality Therapy; Cryosurgery; Curettage; Dermabrasion; Diagnosis, Differential; Electrosurgery; Fluorouracil; Humans; Keratolytic Agents; Keratosis; Laser Therapy; Masoprocol; Precancerous Conditions | 1997 |
2 other study(ies) available for masoprocol and Precancerous Conditions
Article | Year |
---|---|
CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target.
Topics: Adenocarcinoma; Barrett Esophagus; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease Progression; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophagus; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Masoprocol; Precancerous Conditions; RNA, Messenger; RNA, Neoplasm; Tissue Array Analysis | 2005 |
Inhibition by acetylsalicylic acid, a cyclo-oxygenase inhibitor, and p-bromophenacylbromide, a phospholipase A2 inhibitor, of both cirrhosis and enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats.
Topics: Acetophenones; Animals; Aspirin; Choline; Choline Deficiency; Cyclooxygenase Inhibitors; Fatty Liver; gamma-Glutamyltransferase; Glutathione Transferase; Lipoxygenase Inhibitors; Liver; Liver Cirrhosis, Experimental; Liver Neoplasms, Experimental; Male; Masoprocol; Methionine; Oxidative Stress; Phospholipases A; Phospholipases A2; Precancerous Conditions; Quercetin; Rats; Rats, Inbred F344; Time Factors | 1996 |